Sugi Predict

Sugi Predict / Compounds / SCHEMBL19742568

SCHEMBL19742568

SCHEMBL19742568

CN(Cc1ccccc1)C(=O)C1(NC(=O)OC(C)(C)C)CC1

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ CTSL P07711 2/20 0.52
▸ CTSB P07858 2/20 0.52
▸ CTSS P25774 2/20 0.52
▸ AKT1 P31749 3/20 0.49
▸ RAB9A P51151 4/20 0.46
▸ NPC1 O15118 3/20 0.46
▸ RIPK1 Q13546 1/20 0.44
▸ CA12 O43570 2/20 0.42
▸ CA1 P00915 1/20 0.42
▸ CA7 P43166 1/20 0.42
▸ CA14 Q9ULX7 1/20 0.42
▸ CA9 Q16790 1/20 0.42
▸ GHSR Q92847 1/20 0.42
▸ KMT2A Q03164 2/20 0.41
▸ L3MBTL1 Q9Y468 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.40
▸ MEN1 O00255 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19742740 0.83 NPC1 (0.54) RAB9ANPC1RIPK1CA12CA9
SCHEMBL6304830 0.80 CTSL (0.48) CTSLCTSBCTSSAKT1GHSR
SCHEMBL19742775 0.79 AKT1 (0.50) CTSLCTSBCTSSAKT1RAB9A
SCHEMBL2535173 0.77 SYK (0.49) CTSLCTSBCTSSAKT1RAB9A
SCHEMBL5381278 0.76 PPIA (0.49) CTSLCTSBCTSSAKT1CA12
SCHEMBL19177379 0.75 CTSK (0.35) CTSLCA12CA1CA7CA14
SCHEMBL19742566 0.75 CTSL (0.57) CTSLCTSBCTSSAKT1RAB9A
SCHEMBL4254558 0.75 CTSL (0.57) CTSLCTSBCTSSAKT1RAB9A
SCHEMBL22766211 0.75 MEN1 (0.36) CTSLCA12CA1CA7CA14
SCHEMBL21564486 0.74 AKT1 (0.48) CTSLCTSBCTSSAKT1CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109562111-B CK2 inhibitors, compositions and methods thereof 北极星药业股份有限公司 2023-04-04 — — CN disclosed
EP-3474855-B1 CK2 INHIBITORS, COMPOSITIONS AND METHODS THEREOF POLARIS PHARMACEUTICALS INC (US) 2022-01-26 — — EP disclosed
EP-3474855-B1 CK2 INHIBITORS, COMPOSITIONS AND METHODS THEREOF POLARIS PHARMACEUTICALS INC (US) 2022-01-26 — — EP disclosed
EP-3474855-A1 CK2 INHIBITORS, COMPOSITIONS AND METHODS THEREOF Polaris Pharmaceuticals, Inc. (US) 2019-05-01 — — EP disclosed
US-10227344-B2 CK2 inhibitors, compositions and methods thereof POLARIS PHARMACEUTICALS, INC. (US) 2019-03-12 — — US disclosed
US-20170369489-A1 CK2 INHIBITORS, COMPOSITIONS AND METHODS THEREOF POLARIS PHARMACEUTICALS 2017-12-28 — — US disclosed
US-20170369489-A1 CK2 INHIBITORS, COMPOSITIONS AND METHODS THEREOF POLARIS PHARMACEUTICALS 2017-12-28 — — US disclosed
WO-2017223432-A1 CK2 INHIBITORS, COMPOSITIONS AND METHODS THEREOF POLARIS PHARMACEUTICALS (US) 2017-12-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170369489-A1 CK2 INHIBITORS, COMPOSITIONS AND METHODS THEREOF CSNK1A1, CSNK2A1, CSNK2A3 CTSL 2748/4885CTSB 2472/4885CTSS 2136/4885
US-10227344-B2 CK2 inhibitors, compositions and methods thereof CSNK1A1, CSNK2A1, CSNK2A3 CTSL 2748/4885CTSB 2472/4885CTSS 2136/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.